During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed whether risk stratification factors into the ...

In a new observational study published in Cancer, commonly prescribed chronic medications did not affect the efficacy of ...

FOLFIRINOX chemotherapy is feasible in selected elderly patients with pancreatic ductal adenocarcinoma, though toxicity ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive testing and improved communication.

The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...

Marija Balic, MD, provides background on the treatment of triple-negative breast cancer (TNBC) and the emerging potential of ...

She highlights the emergence of axatilimab, a CSF-1R inhibitor that attacks the underlying mechanisms of cGVHD by targeting ...

Artificial intelligence (AI) has the potential to transform biomarker testing in early-stage NSCLC by streamlining data ...